74
Treatment
11.3. HF and Pregnancy
COR LOE
Recommendations
1 C-LD 1. In women with a history of HF or cardiomyopathy,
including previous peripartum cardiomyopathy, patient-
centered counseling regarding contraception and the risks
of cardiovascular deterioration during pregnancy should be
provided.
2b C-LD 2. In women with acute HF caused by peripartum
cardiomyopathy and LVEF <30%, anticoagulation may
be reasonable at diagnosis, until 6 to 8 weeks postpartum,
although the efficacy and safety are uncertain.
3: Harm C-LD 3. In women with HF or cardiomyopathy who are pregnant
or currently planning for pregnancy, ACEi, ARB, ARNi,
MRA, SGLT2i, ivabradine, and vericiguat should not be
administered because of significant risks of fetal harm.
12. Quality Metrics and Reporting
12.1. Performance Measurement
COR LOE
Recommendations
1 B-NR 1. Performance measures based on professionally developed
clinical practice guidelines should be used with the goal of
improving quality of care for patients with HF.
2a B-NR 2. Participation in quality improvement programs, including
patient registries that provide benchmark feedback on
nationally endorsed, clinical practice guideline–based quality
and performance measures can be beneficial in improving the
quality of care for patients with HF.
